Clinical and genetic analysis of psychosis in Parkinson’s disease
Objective: This study aimed to examine the association of seven selected polymorphisms of DRD2, ANKK1, COMT and DAT genes with Parkinson’s disease psychosis (PDP) onset.…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients
Objective: To evaluate the role of COMT gene variations on the pharmacokinetics (PK) of L-dopa in PD patients. Background: Genetic variations in enzymes (MAO-B, COMT),…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease
Objective: To evaluate the pharmacokinetics and pharmacodynamics of opicapone in Parkinson’s disease (PD). Background: Opicapone, a highly selective COMT inhibitor, is approved in Europe and…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations
Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys
Objective: To evaluate the effect of repeated OPC treatments, COMT inhibition versus plasma opicapone level, dose response of COMT inhibition, and systematic and central bioavailability…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…Deletions at 22q11.2 in idiopathic Parkinson’s disease: A combined analysis of GWAS data
Objective: To verify the reported association of Parkinson's disease(PD) with Chromosome 22q11.2 Deletion Syndrome(22q11.2DS) in series of large, independent idiopathic PD case-control studies. Background: PD…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.